ALLOGENE THERAPEUTICS INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
ALLOGENE THERAPEUTICS INC. - More news...
ALLOGENE THERAPEUTICS INC. - More news...
- Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
- Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
- Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
- Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal
- Allogene Therapeutics Reports First Quarter 2022 Financial Results
- Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
- Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022
- Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
- Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences
- Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
- Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
- Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Report
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
- Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022
- Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
- Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
- Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials
- Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
- Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
- Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
- Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
- Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
- Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
- Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update
- Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd Annual Meeting of the American Society of Hematology
- Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021
- Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial
- Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board
- Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
